Delphia Therapeutics
Cambridge, US · 24 employees on LinkedIn · 5 known investors
Find your way into Delphia Therapeutics
Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.
Founders & leadership
KM
Kevin MarksinFounder · President & CEO
Investors · 5
GV (Google Ventures)Mountain View · $250K – $50M
Nextech InvestZurich · $648K – $3.2M
Taiho Ventures, LLCMenlo Park
Alexandriareported · 2 sourcesPasadena
Also in the syndicate · 1
Polaris Partnerslead
Funding
SEC filings, press & company announcements$67M disclosed across 1 round · 2024
- $67MSeries AMay 2024 · 2 sources
Alexandria Venture Investments (lead), GV (lead), Nextech Invest (lead), Polaris Partners (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Delphia Therapeutics do?
- Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies. It focuses on oncology drug discovery and clinical development.
- Who founded Delphia Therapeutics?
- Delphia Therapeutics was founded by Kevin Marks.
- Who are Delphia Therapeutics's investors?
- Delphia Therapeutics's investors include GV (Google Ventures), Nextech Invest, Taiho Ventures, LLC, Alexandria.
- How much funding has Delphia Therapeutics raised?
- Delphia Therapeutics has disclosed $67M raised across 1 round.
- Where is Delphia Therapeutics headquartered?
- Delphia Therapeutics is headquartered in Cambridge, US.